CCS Integrated Cases

CCS case: outpatient COPD with exacerbation history

Clinical Overview and When to Suspect COPD Exacerbation

— Cardinal symptoms (Anthonisen criteria): increased dyspnea, increased sputum volume, increased sputum purulence

— Type 1 = all 3; Type 2 = 2 of 3; Type 3 = 1 plus URI/fever/wheeze

— Established COPD patient with new productive cough, color change of sputum, increased rescue albuterol use, exercise intolerance, nocturnal awakenings

— Prior exacerbation in past 12 months is the single strongest predictor of recurrence ("frequent exacerbator phenotype" = ≥2 moderate or ≥1 severe/year)

— Common triggers: viral URI (rhinovirus, influenza, RSV, SARS-CoV-2), bacterial (H. influenzae, S. pneumoniae, M. catarrhalis, Pseudomonas in advanced disease), air pollution, nonadherence, beta-blocker misuse, cold air

— Group A: 0–1 moderate exacerbation, low symptoms (mMRC 0–1 or CAT <10)

— Group B: 0–1 moderate exacerbation, high symptoms

— Group E: ≥2 moderate or ≥1 hospitalization, regardless of symptoms

Board pearl: A COPD patient with ≥1 severe exacerbation (hospitalization) in the past year automatically becomes GOLD Group E and warrants escalation of maintenance therapy regardless of symptom score — exacerbation history, not just spirometry or symptoms, drives long-term inhaler choice.

COPD = persistent airflow limitation from chronic bronchitis and/or emphysema, post-bronchodilator FEV1/FVC < 0.70

Exacerbation (AECOPD) = acute worsening of respiratory symptoms beyond day-to-day variability requiring additional therapy

When to suspect in the outpatient CCS case:

GOLD ABE classification (2023+ update):

Step 3 outpatient framing: patient is in your office or urgent care — your task is to (1) confirm exacerbation vs mimic, (2) treat acutely, (3) decide home vs ED, (4) optimize maintenance to prevent the next exacerbation

Presentation Patterns and Key History

— Subacute (1–7 days) worsening of baseline dyspnea, often with chest tightness and wheeze

— Sputum becomes thicker, more copious, yellow/green (purulent)

— Reduced exercise tolerance: "can't walk to the mailbox," sleeping in recliner, increased albuterol canisters/week

— Baseline status: mMRC dyspnea (0 = only strenuous; 4 = breathless dressing), 6-minute walk, home O2 use, prior intubations

— Exacerbation history: number in past 12 months, ED visits, hospitalizations, ICU/intubation (predicts severity of current event)

— Current inhalers: LABA/LAMA/ICS combinations, technique, adherence, last refill

— Trigger review: sick contacts, vaccine status (influenza, PCV20/PCV21, RSV ≥60, COVID, Tdap), pollution/wildfire smoke, recent travel

— Red flags suggesting alternative dx: chest pain (ACS, PE), unilateral leg swelling (PE/DVT), orthopnea/PND (HF), hemoptysis (malignancy, PE), fever >38.5 with focal signs (pneumonia)

— Pack-years, current status, readiness to quit (assess stage of change)

— Occupational dusts, biomass fuel, secondhand smoke

— Alpha-1 antitrypsin deficiency should be screened once in every COPD patient, especially if <45 yo, basilar emphysema, family history, or non-smoker

— Recent nonselective beta-blocker initiation, opioids/benzos causing hypoventilation, ACEi cough confounder

— Adherence barriers: cost, inhaler technique, cognitive impairment

Step 3 management: In every COPD visit, document mMRC, CAT score, exacerbations in past year, and inhaler technique — these four data points drive GOLD group assignment and therapy escalation decisions; failure to reassess is a common board distractor showing inappropriate step-up.

Classic AECOPD presentation:

Targeted history checklist for CCS:

Smoking and exposure history:

Medication review for iatrogenic triggers:

Physical Exam Findings and Hemodynamic Assessment

— Mild–moderate: speaking full sentences, RR 20–24, SpO2 88–92% on room air

— Severe: tripoding, pursed-lip breathing, accessory muscle use (SCM, scalenes), 3–4 word dyspnea, diaphoresis

— Impending failure: paradoxical abdominal motion, silent chest, cyanosis, somnolence, asterixis (CO2 narcosis) — send to ED immediately

— SpO2 target in known CO2 retainers: 88–92% (not 100% — risk of worsening hypercapnia via Haldane effect, V/Q mismatch, loss of hypoxic drive)

— Tachycardia, pulsus paradoxus >10 mmHg suggests severe airflow obstruction

— Fever should prompt CXR (pneumonia overlap)

— Prolonged expiratory phase (I:E often 1:3 or 1:4), diffuse expiratory wheeze, rhonchi that clear with cough

— Hyperresonance to percussion, decreased breath sounds, distant heart sounds (hyperinflation)

— Focal crackles or egophony → think pneumonia, not pure AECOPD

— JVD, hepatojugular reflux, RV heave, loud P2, peripheral edema → cor pulmonale or decompensated right heart failure

— Bilateral basilar crackles, S3, orthopnea → LV failure (common comorbidity; up to 30% of COPD patients)

— Unilateral calf swelling, Homans → PE workup

— Clubbing is NOT typical of COPD — if present, evaluate for lung cancer, bronchiectasis, ILD

— Barrel chest, nicotine staining, cachexia (emphysema phenotype)

Key distinction: Wheezing + bilateral basilar crackles + orthopnea + elevated BNP in a smoker is often decompensated HF, not AECOPD — treating with steroids/antibiotics alone misses the diagnosis; obtain BNP and bedside echo/CXR when overlap is suspected ("cardiac asthma").

General appearance — severity triage at a glance:

Vitals to anchor on:

Pulmonary exam:

Cardiac and volume exam (critical for mimics):

Extrapulmonary clues:

Diagnostic Workup — Initial Labs, Imaging, ECG

— Pulse oximetry on room air (and ambulatory if borderline)

— Peak flow if available — compare to personal best

— CXR PA/lateral — order if fever, focal exam, first severe exacerbation, or to exclude pneumonia, pneumothorax, effusion, HF, mass

— ECG — look for new RBBB, RAE ("P pulmonale"), MAT, AFib (common trigger and complication), ischemia

— CBC — leukocytosis (infection), polycythemia (chronic hypoxia), eosinophils (drives ICS decision-making)

— BMP — baseline K+ (β-agonist–induced hypokalemia), bicarb (chronic compensation for hypercapnia, baseline 28–32)

— BNP/NT-proBNP if HF overlap suspected

— Influenza/COVID/RSV PCR during respiratory virus season

— Sputum Gram stain/culture — only if purulent and patient has had recent antibiotics, structural lung disease (bronchiectasis), or prior Pseudomonas

— Outpatient mild–moderate: usually not needed

— Obtain if SpO2 <88%, altered mental status, severe distress, suspected CO2 retention — VBG correlates well for pH and CO2 screening; ABG remains gold standard if precise PaO2 needed

— Blood eos ≥300 cells/µL predicts ICS responsiveness and reduced exacerbations

— Eos <100 → ICS unlikely to help and may increase pneumonia risk

CCS pearl: In the simulated office encounter, order pulse ox, CXR, CBC with diff (for eosinophils), BMP, and ECG as the initial set for any AECOPD; advance the clock 30–60 minutes and reassess oxygenation and mental status before deciding home vs ED disposition.

Outpatient AECOPD — focused initial orders (CCS office setting):

ABG vs VBG:

Eosinophils — key biomarker:

Diagnostic Workup — Advanced and Confirmatory Studies

— Defer formal PFTs until ≥4–6 weeks after exacerbation resolves

— Confirms diagnosis: post-bronchodilator FEV1/FVC <0.70

— GOLD severity by FEV1 % predicted: GOLD 1 ≥80%, 2 = 50–79%, 3 = 30–49%, 4 <30%

— Reversibility >12% and 200 mL doesn't exclude COPD but suggests asthma–COPD overlap

— DLCO — reduced in emphysema; helps distinguish from asthma (normal/elevated DLCO)

— Lung volumes — increased TLC, RV (hyperinflation/air trapping)

— 6-minute walk test — desaturation <88% qualifies for ambulatory O2; baseline for pulmonary rehab

— High-resolution CT chest — if hemoptysis, suspected bronchiectasis, lung cancer screening eligible, or evaluating for lung volume reduction/bullectomy

— Echocardiogram — if signs of pulmonary hypertension, cor pulmonale, or HF overlap

— Alpha-1 antitrypsin level — once in every COPD patient (AAT level + phenotyping if <11 µmol/L or 80 mg/dL)

— Sleep study — if obesity, witnessed apneas, daytime hypercapnia disproportionate to FEV1 ("overlap syndrome" COPD + OSA)

— Low-dose CT annually for adults 50–80, ≥20 pack-years, current smoker or quit within 15 years (USPSTF 2021)

— Influenza annually; PCV20 or PCV21 once; RSV once ≥60; Tdap; COVID-19 updated; zoster ≥50

Board pearl: Do NOT order spirometry during an acute exacerbation — values are unreliable and may overestimate severity. Schedule post-recovery PFTs at 4–6 weeks to confirm diagnosis and stage; this timing question is a common Step 3 distractor.

Spirometry — diagnostic cornerstone but NOT during acute exacerbation:

Additional workup in select patients:

Lung cancer screening overlap:

Vaccination status verification (preventive layer of CCS case):

Risk Stratification and First-Line Management Logic

— Home management appropriate if: ambulatory baseline, SpO2 ≥90% on room air or home O2, no AMS, able to eat/drink, intact home support, no significant comorbidity decompensation

— Send to ED if: severe dyspnea at rest, SpO2 <88% (or <baseline), accessory muscle use, cyanosis, AMS, hemodynamic instability, failed outpatient therapy, comorbid pneumonia/PE/HF, inability to manage at home

— Short-acting bronchodilators (SABA + SAMA): albuterol 2.5 mg + ipratropium 0.5 mg nebulized, or 4–8 puffs MDI with spacer, q1h × 1–3 doses, then q4–6h

— Systemic corticosteroid: prednisone 40 mg PO daily × 5 days (REDUCE trial — 5 days noninferior to 14)

— Antibiotic if Anthonisen criteria met (≥2 cardinal symptoms with one being increased sputum purulence, OR mechanical ventilation): typically 5–7 days

— Controlled O2 if hypoxic: nasal cannula titrated to SpO2 88–92%

— Re-check vitals and SpO2 at 30–60 minutes

— Blood eos ≥300 → strong case for ICS-containing maintenance

— Eos <100 → consider LABA/LAMA without ICS

— Escalate to triple therapy (LABA + LAMA + ICS) if eos ≥100

— Consider roflumilast (chronic bronchitis phenotype, FEV1 <50%) or azithromycin 250 mg daily or 500 mg 3×/wk (former smokers preferred)

Step 3 management: For outpatient AECOPD, the "steroid + bronchodilator ± antibiotic" trio drives acute therapy; the next visit must address maintenance escalation because treating the exacerbation without revising the inhaler regimen is the classic Step 3 wrong-answer trap.

First decision: can this patient go home?

Outpatient AECOPD bundle — order at time zero in clinic:

Eosinophil-guided decisions:

Frequent exacerbator pathway (≥2/yr or ≥1 hospitalization):

Pharmacotherapy — First-Line Regimens

— Albuterol 2.5 mg nebulized or 90 µg MDI 4–8 puffs with spacer q1h × 3, then q4–6h

— Ipratropium 0.5 mg neb or 17 µg MDI 2 puffs q6h (additive with SABA in acute setting)

— Prednisone 40 mg PO daily × 5 days — no taper needed for short courses; methylprednisolone IV only if NPO/severe

— Antibiotics (5–7 days) — choice by risk:

· Uncomplicated: azithromycin, doxycycline, or amoxicillin-clavulanate

· Risk for Pseudomonas (recent hospitalization, frequent antibiotics, FEV1 <50%, structural lung disease, chronic steroids): levofloxacin 750 mg daily or ciprofloxacin

· Avoid azithromycin if QTc prolongation, recent macrolide use

— Group A: short- or long-acting bronchodilator (LAMA or LABA)

— Group B: LABA + LAMA combo (e.g., umeclidinium/vilanterol, tiotropium/olodaterol)

— Group E:

· LABA + LAMA if eos <300

· LABA + LAMA + ICS (triple therapy) if eos ≥300, or eos ≥100 with continued exacerbations

· Examples: fluticasone/umeclidinium/vilanterol (Trelegy), budesonide/glycopyrrolate/formoterol (Breztri)

— Roflumilast (PDE4 inhibitor): chronic bronchitis + FEV1 <50% + exacerbations; SE = weight loss, diarrhea, psychiatric effects

— Azithromycin 250 mg daily: reduces exacerbations; check QTc, baseline LFTs, audiogram

— Dupilumab (2024 approval): eos ≥300 on triple therapy with continued exacerbations

Board pearl: ICS monotherapy is NEVER appropriate in COPD (unlike asthma) — it increases pneumonia risk without benefit when used alone; always pair with a long-acting bronchodilator backbone.

Acute AECOPD pharmacology (outpatient):

Maintenance therapy by GOLD ABE group:

Add-on options for frequent exacerbators on triple therapy:

Adjunctive Management and Procedural Considerations

— Slows FEV1 decline to near-normal rate, reduces exacerbations and mortality

— First-line pharmacotherapy: varenicline (most effective monotherapy, start 1 week before quit date) OR combination NRT (patch + lozenge/gum)

— Bupropion SR as alternative; avoid in seizure disorder, eating disorders

— Behavioral counseling at every visit (5 A's: Ask, Advise, Assess, Assist, Arrange)

— PaO2 ≤55 mmHg or SpO2 ≤88% at rest, OR

— PaO2 56–59 mmHg or SpO2 89% WITH cor pulmonale, polycythemia (Hct >55%), or evidence of pulmonary HTN

— Goal: ≥15 hours/day; only intervention besides smoking cessation proven to reduce mortality in severe COPD with chronic hypoxemia

— Acute: BiPAP for hypercapnic respiratory failure (pH <7.35, PaCO2 >45) — reduces intubation and mortality

— Chronic home NIV: persistent hypercapnia (PaCO2 ≥52) after recovery from exacerbation

— Indicated for mMRC ≥2 or post-exacerbation; enroll within 4 weeks of hospital discharge (reduces readmission)

— 6–12 weeks of exercise training, education, nutritional counseling, psychosocial support

— Endobronchial valves (Zephyr) for severe heterogeneous upper-lobe emphysema with hyperinflation

— Lung volume reduction surgery (LVRS): upper-lobe predominant emphysema + low exercise capacity (NETT trial)

— Lung transplant: BODE index 7–10, FEV1 <20% with DLCO <20% or homogeneous emphysema

— Bullectomy for giant bullae >1/3 hemithorax

CCS pearl: After an AECOPD, order pulmonary rehab referral and confirm smoking cessation pharmacotherapy at the discharge/follow-up visit — both are high-yield Step 3 expected orders and reduce 30-day readmission.

Smoking cessation — the single most effective intervention:

Oxygen therapy criteria — long-term home O2 (LTOT):

Noninvasive ventilation (NIV):

Pulmonary rehabilitation:

Surgical/procedural options for advanced disease:

Special Populations — Elderly and Renal/Hepatic Impairment

— Polypharmacy review at every visit — Beers criteria flags: nonselective anticholinergics (but inhaled ipratropium/tiotropium are safe), benzodiazepines, opioids (respiratory depression risk)

— Inhaler technique declines with age and cognition — switch to soft-mist (Respimat) or nebulizer if MDI coordination fails; assess pinch grip for DPIs

— Fall risk: chronic steroids → osteoporosis; check DEXA, calcium 1200 mg + vitamin D 800 IU, bisphosphonate if T-score ≤−2.5 or fragility fracture

— Cognitive screening (MoCA) before complex regimens; engage caregiver

— Cardiovascular disease (leading cause of death in mild–moderate COPD) — cardioselective beta-blockers (metoprolol, bisoprolol) are SAFE and indicated for HF/CAD; do not withhold

— Osteoporosis, depression/anxiety, sarcopenia, OSA, lung cancer, diabetes (worsened by steroids)

— Most inhaled therapies require no dose adjustment (minimal systemic absorption)

— Levofloxacin — adjust for CrCl <50; avoid in CrCl <20 unless necessary; tendinopathy risk in elderly

— Roflumilast — no renal adjustment but avoid in moderate–severe hepatic impairment (Child-Pugh B/C)

— Watch β-agonist–induced hypokalemia in patients on diuretics

— Theophylline (rarely used) — narrow therapeutic window, hepatic metabolism, multiple interactions; check levels

— Azithromycin — hepatotoxicity risk; monitor LFTs at baseline

— Acetaminophen preferred over NSAIDs for analgesia (NSAIDs may trigger bronchospasm in aspirin-sensitive subset)

Key distinction: Cardioselective β1-blockers do NOT worsen COPD and should not be withheld when indicated for HFrEF, post-MI, or rate control — withholding them is a common Step 3 wrong answer driven by outdated teaching.

Elderly COPD patients (>65, often the CCS demographic):

Comorbidities to co-manage:

Renal impairment:

Hepatic impairment:

Special Populations — Pregnancy, Younger Patients, and Phenotypes

— COPD is rare in reproductive-age women but consider in alpha-1 antitrypsin deficiency, severe asthma–COPD overlap, or cystic fibrosis

— Safe in pregnancy: SABAs (albuterol — extensive safety data), LABAs, ICS (budesonide preferred), ipratropium; prednisone for exacerbations (small cleft palate risk in T1, but maternal hypoxia is worse)

— Avoid: fluoroquinolones (cartilage concerns), tetracyclines after 18 weeks (teeth/bone), roflumilast (limited data)

— Maintain SpO2 ≥95% in pregnancy (fetal O2 demand higher than nonpregnant target)

— Alpha-1 antitrypsin deficiency — basilar/panacinar emphysema, family history, liver disease; check AAT level + Pi typing; treatment = IV AAT augmentation (pooled human AAT) weekly

— Bronchiectasis (post-infectious, CF, primary ciliary dyskinesia, immunodeficiency)

— Heavy cannabis or vaping history (EVALI, bullous disease)

— Features of both: prior asthma, atopy, eosinophilia, significant bronchodilator reversibility, variable symptoms

— ICS is essential here (unlike pure COPD) — always include ICS in regimen; LABA/LAMA/ICS often appropriate

— Never use LABA monotherapy in ACO (asthma death risk)

— Common in immigrants from high-TB-burden regions and women with indoor cooking-fire exposure; same treatment principles, screen for prior TB and bronchiectasis

— Refer at BODE 5–6; list at BODE 7–10, FEV1 <20%, severe hypercapnia, or pulmonary HTN despite optimal therapy

Board pearl: Screen every COPD patient at least once for alpha-1 antitrypsin deficiency — GOLD recommends universal screening regardless of age or smoking history; missing this in a young or non-smoker patient is a classic test trap.

Pregnancy with COPD (uncommon but tested):

Young patients (<45) with COPD — always investigate:

Asthma–COPD overlap (ACO):

Post-tuberculosis and biomass-exposure COPD:

Lung transplant candidates:

Complications and Adverse Outcomes

— Acute hypercapnic respiratory failure — pH <7.35, PaCO2 >45; → BiPAP; intubate if AMS, hemodynamic instability, failure of NIV

— Pneumothorax — sudden worsening dyspnea, unilateral decreased breath sounds; bullous emphysema predisposes; CXR confirms; chest tube if large or tension

— Pulmonary embolism — up to 20% of severe AECOPD without obvious trigger; have low threshold for CT-PA if D-dimer elevated above age-adjusted threshold

— Pneumonia — overlapping diagnosis; treat as CAP if focal infiltrate

— Cardiac arrhythmias — multifocal atrial tachycardia (MAT) is classic (≥3 P-wave morphologies, irregular); treat underlying hypoxia/hypercapnia, correct K+/Mg2+; avoid β-blockers acutely; verapamil or metoprolol for rate control once stable

— Acute MI and demand ischemia — troponin elevation correlates with mortality

— Cor pulmonale and pulmonary hypertension — RV strain, edema, hepatomegaly; treat hypoxia with LTOT (mainstay); diuretics cautiously

— Secondary polycythemia — Hct >55% from chronic hypoxia; treat with O2, phlebotomy if symptomatic

— Cachexia and sarcopenia — independent mortality predictor; nutritional support, resistance training in rehab

— Osteoporosis — from steroids, low BMI, inactivity, hypogonadism, smoking

— Depression and anxiety in 40%; screen with PHQ-9/GAD-7; SSRIs safe

— Lung cancer — leading cause of death in mild–moderate COPD; ensure annual LDCT if eligible

— ICS → oral candidiasis (rinse mouth), pneumonia, hoarseness, skin thinning

— Chronic prednisone → hyperglycemia, HTN, osteoporosis, adrenal suppression, cataracts

— β-agonist → tremor, tachycardia, hypokalemia

CCS pearl: Sudden, unexplained worsening of AECOPD without typical triggers should prompt evaluation for PE and pneumothorax; order CT-PA and CXR before assuming antibiotic/steroid failure.

Acute complications of AECOPD:

Chronic complications:

Iatrogenic complications:

When to Escalate Care — ED, Inpatient, ICU

— SpO2 <88% despite supplemental O2 titration, or drop ≥4% from baseline

— Use of accessory muscles, paradoxical chest wall motion, cyanosis

— Altered mental status, somnolence, confusion (CO2 narcosis)

— Hemodynamic instability, new arrhythmia, chest pain

— Inability to tolerate PO, no home support, failed prior outpatient therapy in past 48 hours

— Comorbid acute illness: pneumonia with sepsis, decompensated HF, suspected PE

— Need for supplemental O2 beyond baseline

— Failure to respond to ED bronchodilator/steroid therapy

— Significant comorbidity decompensation

— Inadequate home support, social factors

— Severe dyspnea unresponsive to initial emergency therapy

— Altered mental status (confusion, lethargy, coma)

— Persistent or worsening hypoxemia (PaO2 <40 or SpO2 <90% on supplemental O2), severe/worsening hypercapnia (PaCO2 >60), or respiratory acidosis (pH <7.25) despite NIV

— Need for invasive mechanical ventilation

— Hemodynamic instability requiring vasopressors

— Pulmonology — frequent exacerbator, diagnostic uncertainty, advanced therapies (biologics, transplant evaluation), suspected ACO or AATD

— Cardiology — suspected HF, cor pulmonale, arrhythmia management

— Palliative care — BODE ≥7, frequent hospitalizations, mMRC 4, refractory dyspnea, goals-of-care clarification

— Thoracic surgery — bullae, LVRS/transplant candidate

— Smoking cessation/behavioral health — refractory tobacco dependence, depression

Step 3 management: BiPAP is the first-line ventilatory support for AECOPD with hypercapnic respiratory failure (pH <7.35, PaCO2 >45) and alert patient who can protect airway — initiating BiPAP in the ED reduces intubation rate by ~50% and is the expected next step before considering intubation.

Send from clinic to ED (call EMS, not patient drives) when:

Inpatient admission criteria (ED → ward):

ICU admission criteria:

Consult triggers:

Key Differentials — Same-Category Respiratory Causes

— Earlier onset of disease (often <40), atopy, allergic triggers, episodic with full recovery between, significant bronchodilator reversibility (>12% and 200 mL), normal/elevated DLCO

— Eosinophilia and elevated FeNO support

— Treat acute attack similarly (SABA, steroids) but maintenance always includes ICS; LABA monotherapy is contraindicated

— Chronic copious purulent sputum, hemoptysis, recurrent infections; HRCT shows airway dilation, tram tracks, signet rings

— Common pathogens: H. influenzae, Pseudomonas, NTM

— Treatment: airway clearance, inhaled antibiotics (tobramycin), prolonged courses (14 days)

— Focal infiltrate on CXR, fever, leukocytosis, productive cough; CURB-65/PSI for triage

— Outpatient empiric: amoxicillin or doxycycline (or macrolide if local resistance low); add macrolide/β-lactam combo if comorbidities

— Self-limited; antibiotics not indicated unless pertussis suspected or in COPD baseline

— Acute pleuritic chest pain, hemoptysis, unilateral leg swelling, tachycardia out of proportion; Wells/PERC; CT-PA

— Sudden severe dyspnea in patient with bullous disease; unilateral findings; upright CXR

— Bibasilar fine "Velcro" crackles, restrictive PFTs, low DLCO, reticular changes/honeycombing on HRCT

— Inspiratory stridor (not expiratory wheeze), flattened inspiratory loop on flow-volume curve

Key distinction: Asthma vs COPD on PFTs — asthma typically shows fully reversible airflow obstruction post-bronchodilator and preserved/elevated DLCO; COPD shows persistent FEV1/FVC <0.70 and reduced DLCO when emphysema predominates.

Asthma exacerbation:

Asthma–COPD overlap (ACO): features of both; require ICS in regimen

Bronchiectasis exacerbation:

Community-acquired pneumonia:

Acute bronchitis (in patient without underlying COPD):

Pulmonary embolism:

Pneumothorax:

Interstitial lung disease (IPF, hypersensitivity pneumonitis):

Upper airway obstruction / vocal cord dysfunction:

Key Differentials — Non-Respiratory Mimics

— Orthopnea, PND, bibasilar crackles, S3, JVD, peripheral edema, elevated BNP/NT-proBNP, pulmonary edema on CXR

— Echo shows reduced EF or diastolic dysfunction

— Treat with diuresis (furosemide), nitrates, afterload reduction; bronchodilators alone won't fix

— Dyspnea may be the only symptom in elderly, women, diabetics ("anginal equivalent")

— ECG, troponin mandatory; demand ischemia common during AECOPD

— Atrial fibrillation with RVR — palpitations, irregular pulse, dyspnea; rate control, anticoagulation per CHA2DS2-VASc

— MAT — characteristic of severe COPD with hypoxia

— Exertional dyspnea, fatigue, pallor; CBC; treat underlying cause

— Group 1 PAH (idiopathic, connective tissue, drug-induced), Group 4 CTEPH (post-PE) — RHC for confirmation

— Tachypnea with normal SpO2 and no hypoxia, perioral tingling, carpopedal spasm (hyperventilation alkalosis); diagnosis of exclusion in COPD patient

— Daytime hypercapnia disproportionate to obstruction, witnessed apneas, morning headaches; polysomnography; CPAP/BiPAP

— All can mimic or worsen dyspnea; consider when symptoms outpace PFT findings

— Up to 20% of unexplained AECOPD; always reconsider when atypical features present

— Common COPD trigger; treat with PPI when symptomatic; reduces exacerbation frequency

Board pearl: In a smoker with wheezing + orthopnea + lower-extremity edema + elevated BNP, the answer is often diuresis for HF, not steroids for COPD — overlap is common, and treating both diagnoses simultaneously is frequently correct.

Decompensated heart failure ("cardiac asthma"):

Acute coronary syndrome:

Arrhythmias:

Anemia:

Pulmonary hypertension (other than cor pulmonale):

Anxiety/panic disorder:

Obesity-hypoventilation syndrome / OSA overlap ("overlap syndrome"):

Deconditioning, thyroid disease, GERD with microaspiration:

Pulmonary embolism (re-emphasized):

Gastroesophageal reflux:

Secondary Prevention and Long-Term Discharge Plan

— Reassess GOLD group — most post-exacerbation patients are Group E

— Step up: monotherapy → LABA/LAMA → triple therapy (if eos ≥100 with continued exacerbations on dual)

— Verify and document inhaler technique at every visit; demonstration > verbal instruction

— Varenicline 0.5 mg → titrate to 1 mg BID × 12 weeks (extend to 24 if successful)

— Combination NRT, bupropion alternatives

— Behavioral support, quitline (1-800-QUIT-NOW), text/app programs

— Influenza annually

— PCV20 or PCV21 (one-time pneumococcal)

— RSV vaccine age ≥60

— COVID-19 per current CDC schedule

— Tdap every 10 years, zoster ≥50

— Refer within 4 weeks of hospital discharge — class IA evidence for reduced readmission

— 8–12 weeks, 2–3 sessions/week

— Cardiovascular risk: statin if indicated, BP control, continue cardioselective β-blockers

— Osteoporosis: DEXA, calcium/vitamin D, bisphosphonate

— Depression/anxiety screening with treatment

— OSA evaluation if overlap suspected

— Written COPD action plan — green/yellow/red zones with self-management instructions; rescue prednisone/antibiotic prescriptions for early use in selected reliable patients

— Discuss goals of care, intubation preferences, POLST in BODE ≥5 or after hospitalization

Step 3 management: Every post-exacerbation visit must explicitly include — (1) inhaler step-up review, (2) smoking cessation pharmacotherapy, (3) vaccination update, (4) pulmonary rehab referral, (5) written action plan — missing any of these is a common Step 3 wrong-answer pattern.

Maintenance inhaler optimization after exacerbation (the critical Step 3 step):

Smoking cessation — repeat at every encounter:

Vaccinations — confirm and update at discharge:

Pulmonary rehabilitation:

Long-term oxygen therapy if criteria met (PaO2 ≤55 or SpO2 ≤88%)

Comorbidity optimization:

Action plan:

Advance care planning:

Follow-Up, Monitoring, and Rehab Cadence

— Phone or telehealth check at 48–72 hours — symptom trajectory, medication adherence, side effects (steroid hyperglycemia in diabetics)

— In-person visit at 1–2 weeks — full reassessment, inhaler technique, vaccinations, mood screen, smoking cessation reinforcement

— 4–6 weeks post-exacerbation — perform/repeat spirometry to confirm baseline and recalibrate GOLD staging

— 3 months — assess maintenance regimen effectiveness, CAT/mMRC, exacerbations since last visit; pulmonary rehab progress

— Every 3–6 months thereafter if stable; monthly if frequent exacerbator or on home O2

— Symptoms: mMRC dyspnea, CAT score, rescue inhaler use/week, sputum changes, nocturnal symptoms

— Exacerbations: count moderate (steroid/antibiotic course) and severe (ED/hospital) in past 3–12 months

— Vitals: SpO2 on room air; BMI/weight (cachexia and weight loss are mortality predictors)

— Adherence and technique: ask "show me how you use your inhaler"; refill records

— Adverse effects: oral thrush (ICS), tremor/tachycardia (β-agonist), bone density (steroids)

— Comorbidities: BP, A1c if diabetic or on steroids, lipids, depression screen

— Begin within 4 weeks post-discharge; 2–3 sessions/week × 8–12 weeks

— Maintenance program afterward; home exercise program reinforcement

— Pulse oximeter if on LTOT

— Symptom diary or app

— Action plan with rescue medications

— Reconcile medications at every transition (hospital → home, ED → clinic)

— Send visit summary to PCP and pulmonologist

— Engage caregivers/family

CCS pearl: Schedule the first post-discharge contact within 48–72 hours (phone or visit) — early follow-up after AECOPD reduces 30-day readmission and is the most commonly missed order on Step 3 outpatient COPD scenarios.

Post-AECOPD follow-up timeline (CCS-style outpatient cadence):

What to monitor at each visit:

Pulmonary rehabilitation cadence:

Home monitoring tools:

Care transitions:

Ethical, Legal, and Patient Safety Considerations

— COPD is a life-limiting illness — 5-year mortality after first hospitalization approaches 50%

— Initiate goals-of-care discussions early: intubation preferences, NIV trials, hospice eligibility

— Document POLST/MOLST, healthcare proxy, code status — especially in BODE ≥5 or after ICU admission

— Avoid the "surprise question" trap: "Would you be surprised if this patient died in the next 12 months?" — if no, palliative care referral is appropriate alongside disease-modifying therapy

— Steroid pulse therapy in patient with poorly controlled diabetes — disclose hyperglycemia risk and provide a glucose-monitoring plan

— Azithromycin chronic prophylaxis — disclose QTc, hearing loss risk, and macrolide resistance implications; obtain baseline EKG and audiogram

— Lung volume reduction surgery — high morbidity; decision aid and multidisciplinary evaluation required

— Medication reconciliation at every transition prevents duplicate inhaler classes (e.g., two LABAs) — a documented Joint Commission sentinel event source

— Inhaler technique errors occur in >70% of patients — direct observation, not self-report

— Steroid taper miscommunication — clarify that 5-day prednisone for AECOPD does not need taper

— Tuberculosis — reportable if discovered in workup

— Occupational lung disease — report to OSHA/state programs (silica, coal, asbestos)

— Impaired driving — patients with severe hypoxia, syncope, or cognitive impairment from CO2 retention; counsel and document

— Address insurance coverage of varenicline, NRT; many state Medicaid plans cover quit lines and pharmacotherapy

— Opioids (low-dose morphine) appropriate for refractory dyspnea in advanced COPD — do not withhold for fear of respiratory depression; symptom relief is the goal

Board pearl: Low-dose oral or sublingual morphine for refractory dyspnea in advanced COPD is standard palliative care and supported by ATS/ERS guidelines — withholding it out of fear of hastening death is an outdated and tested misconception.

Advance care planning and goals of care:

Informed consent edge cases:

Patient safety in transitions of care:

Mandatory reporting and public health:

Smoking cessation and equity:

End-of-life care:

High-Yield Associations and Rapid-Fire Facts

Step 3 management: When the stem describes a COPD patient with ≥2 exacerbations/year, eos ≥300, on LABA/LAMA — the next step is add ICS (triple therapy), not antibiotics or oral steroids prophylactically.

Mortality interventions in COPD (memorize): smoking cessation, long-term oxygen (if hypoxic), noninvasive ventilation (acute hypercapnic failure), lung volume reduction in selected patients, lung transplant — these reduce mortality; most inhalers reduce exacerbations and symptoms but not mortality

GOLD ABE 2023 update: "C" and "D" merged into "E" (exacerbations); decision is driven by exacerbation history, not just symptom score

Anthonisen criteria: ↑dyspnea, ↑sputum volume, ↑sputum purulence — antibiotics indicated if ≥2, especially with purulence

Eosinophil thresholds: ≥300 favors ICS, <100 against ICS

Pseudomonas risk factors: recent hospitalization, frequent antibiotics, FEV1 <50%, structural lung disease, chronic steroids — cover with antipseudomonal fluoroquinolone or β-lactam

Cardioselective β-blockers (metoprolol, bisoprolol) are SAFE and beneficial in COPD with HF/CAD

MAT is pathognomonic for severe pulmonary disease — ≥3 P-wave morphologies, irregular rhythm; treat hypoxia, not the rhythm

Alpha-1 antitrypsin deficiency: screen once in every COPD patient; basilar emphysema, liver disease, young/non-smoker

BODE index: BMI, Obstruction (FEV1), Dyspnea (mMRC), Exercise (6MWD) — predicts mortality

Prednisone 40 mg × 5 days — REDUCE trial; no taper needed

Pulmonary rehab within 4 weeks of discharge — class IA evidence

Vaccines for COPD: influenza, PCV20/PCV21, RSV ≥60, COVID, Tdap, zoster

LDCT lung cancer screening: 50–80, ≥20 pack-years, current smoker or quit <15 years

Home O2 criteria: PaO2 ≤55 or SpO2 ≤88%; or 56–59/89% with cor pulmonale or Hct >55%

Roflumilast: chronic bronchitis + FEV1 <50% + exacerbations; SE = weight loss, diarrhea, psych

Azithromycin 250 mg daily: prophylaxis in frequent exacerbators (former smokers); check QTc and audiogram

Dupilumab (2024): add-on for eos ≥300 on triple therapy

ICS monotherapy is wrong in COPD; always pair with a long-acting bronchodilator

Board Question Stem Patterns

— 68-year-old smoker hospitalized for 2nd AECOPD this year, on LABA/LAMA, eos 320. After discharge, next step?

— Answer: Escalate to triple therapy (LABA/LAMA/ICS), refer to pulmonary rehab within 4 weeks, smoking cessation pharmacotherapy

— Distractors: continue current regimen, add chronic prednisone, add inhaled antibiotic

— Patient discharged after AECOPD. When should the first post-discharge contact occur?

— Answer: 48–72 hours (phone or in-person), then in-person within 1–2 weeks

— COPD patient with recurrent pneumonia on fluticasone/salmeterol, eos 60. Next step?

— Answer: Discontinue ICS, switch to LABA/LAMA (low eos + pneumonia risk)

— COPD + HFrEF on metoprolol succinate develops AECOPD. Action regarding β-blocker?

— Answer: Continue cardioselective β-blocker; do not stop

— AECOPD with increased dyspnea and sputum volume but clear sputum. Antibiotics?

— Answer: Do not give antibiotics (does not meet Anthonisen criteria — needs ≥2 with purulence component)

— 38-year-old non-smoker with basilar emphysema. Test?

— Answer: Alpha-1 antitrypsin level

— When to perform PFTs after AECOPD?

— Answer: 4–6 weeks after resolution

— ECG shows ≥3 P-wave morphologies in AECOPD. Treatment?

— Answer: Treat underlying hypoxia/hypercapnia, correct K+ and Mg2+; verapamil or metoprolol if rate control needed

— BODE 8, recurrent hospitalizations, mMRC 4. Next step?

— Answer: Palliative care referral alongside ongoing optimal therapy; goals-of-care discussion; consider low-dose opioid for refractory dyspnea

— Outpatient COPD visit, vaccines up to date except — answer asks about RSV (≥60), PCV20/PCV21, influenza, COVID booster

Board pearl: When in doubt on a Step 3 COPD stem, the right answer usually involves both treating the acute issue AND adjusting maintenance/preventive care — single-issue answers are typically wrong.

Stem 1 — The "step-up after exacerbation" question:

Stem 2 — The "follow-up cadence" question:

Stem 3 — The "ICS hesitation" question:

Stem 4 — The "β-blocker withdrawal" trap:

Stem 5 — The "antibiotic decision" question:

Stem 6 — The "young COPD" question:

Stem 7 — The "post-exacerbation spirometry timing" question:

Stem 8 — The "MAT" question:

Stem 9 — The "advance care" question:

Stem 10 — The "vaccine bundle" question:

One-Line Recap

— Acute therapy: SABA + SAMA q4–6h, prednisone 40 mg × 5 days, antibiotics 5–7 days if ≥2 Anthonisen criteria with purulent sputum; O2 to SpO2 88–92%; BiPAP for pH <7.35 with PaCO2 >45

— Maintenance escalation: Group E with eos ≥100 and continued exacerbations on LABA/LAMA → add ICS (triple therapy); add roflumilast (chronic bronchitis, FEV1 <50%) or azithromycin (former smokers) for refractory frequent exacerbators; consider dupilumab if eos ≥300

— Prevention pillars: smoking cessation (varenicline first-line), vaccines (influenza, PCV20/PCV21, RSV ≥60, COVID, Tdap, zoster), pulmonary rehab within 4 weeks, LTOT if PaO2 ≤55 or SpO2 ≤88%, written action plan

— Follow-up cadence: phone within 48–72 hours, in-person at 1–2 weeks, spirometry at 4–6 weeks, then every 3–6 months; reconcile inhalers, observe technique, screen for depression and comorbidities at every visit

— Don't miss: alpha-1 antitrypsin screen once in every patient, continue cardioselective β-blockers when indicated, evaluate for PE/pneumothorax when AECOPD is atypical, initiate palliative care when BODE ≥5 or after ICU stay, and treat refractory dyspnea with low-dose opioids

Step 3 management: The defining Step 3 move is closing the loop after the exacerbation — escalate the inhaler, refer to rehab, update vaccines, prescribe cessation pharmacotherapy, and book the 72-hour follow-up; these longitudinal orders, not the acute prednisone, are what distinguish the correct Step 3 answer from the Step 2 answer.

One-liner: Outpatient COPD with prior exacerbations is managed by treating acute flares with bronchodilators + 5-day prednisone ± antibiotics (Anthonisen-guided), then escalating maintenance based on GOLD ABE group and blood eosinophils, while layering pulmonary rehab, smoking cessation, vaccinations, and early post-discharge follow-up to prevent the next event.

Rapid recap bullets: